Home » Drug Information » FDA Approved Drugs » 1998
Medical Areas: Cardiology/Vascular Diseases
View By:YearCompanyConditionsTherapeutic AreasDrug Names
Agrylin (anagrelide HCL)
The following drug information is obtained from various newswires, published
medical journal articles, and medical conference presentations.
Company: Roberts Pharmaceutical
Approval Status: Approved December 1998
Treatment Area: Cardiology
Agrylin Capsules are indicated for the treatment of patients
with Essential Thrombocythemia to reduce the elevated platelet
count and the risk of thrombosis.
Agrylin Capsules are also indicated for the treatment of
patients with thrombocythemia, secondary to myeloproliferative
disorders, to reduce the elevated platelet count and the risk of
thrombosis and to ameliorate associated symptoms including
These include the following: congestive heart failure,
myocardial infarction, cardiomyopathy, cardiomegaly, complete heart
block, atrial fibrillation, cerebrovascular accident, pericarditis,
pulmonary infiltrates, pulmonary fibrosis, pulmonary hypertension,
pancreatitis, gastric/duodenal ulceration, and seizure.